CD86 and neoplasm: Immune profiling showed CWP + X-ray + aPD-L1 treatment enhanced mature DCs (CD80+CD86+) by 24.5% and tumor-infiltrating CD8+ T cells by 4.8% versus controls (Fig. 2e, f), confirming enhanced antitumor immunity through ICD potentiation.